Aequus Pharmaceu - AQSZF STOCK NEWS

Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) has secured short-term financing through a C$2 million unsecured demand loan from CEO Doug Janzen. This funding aims to retire convertible debentures due May 2, 2022. Janzen emphasized the loan will lower interest costs and support the company’s growth strategy, particularly with its Zimed PF product progressing through Health Canada's review. The loan bears a 2.5% interest rate, and a long-term financing arrangement is in the works. The transaction is classified as a related party transaction, exempt from formal approval under applicable regulations.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announced the resignation of Mr. Jason Flowerday from its Board of Directors. CEO Douglas Janzen expressed gratitude for Flowerday's contributions and wished him success in future endeavors. Aequus is focused on developing and promoting differentiated pharmaceuticals, with ongoing efforts in ophthalmology and transplant markets. The company aims to expand its Canadian commercial platform by launching additional products, either developed internally or acquired through licensing.

Aequus Pharmaceuticals has extended its promotional service agreement with Sandoz for Tacrolimus IR until December 31, 2022. Since 2016, Aequus has driven nearly 20% CAGR for the Sandoz Tacrolimus brand through targeted promotional strategies. Despite pandemic challenges, the company has maintained cost-effective and high-quality solutions for patients and physicians. Aequus aims to enhance its partnership with Sandoz, focusing on commercializing specialty products across Canada.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announced a one-year extension of promotional services terms with Sandoz Canada Inc. for its Vistitan eye drops, which treat elevated eye pressure in glaucoma patients. This extension builds on a four-year relationship, reflecting a consistent growth of over 30% CAGR for the Vistitan brand during this period. Aequus aims to expand its portfolio in the Canadian eye care market by investing in new strategic products and partners.

Aequus Pharmaceuticals has submitted a New Drug Submission (NDS) to Health Canada for its preservative-free bimatoprost 0.03% eye drops, Zimed PF. This marks the first submission of a preservative-free glaucoma treatment in a multi-dose format in Canada. The formulation aims to provide a safer option for patients sensitive to preservatives. The review period by Health Canada is expected to be 355 days, although delays could occur due to COVID-19 backlogs. Aequus emphasizes its commitment to innovative ocular therapies.

Aequus Pharmaceuticals Inc. reported its second-largest revenue quarter, achieving $712,036 in revenue, a 9% increase from Q2 and 15% year-over-year. Direct-to-clinic sales surged 131% compared to the last quarter. Despite revenue growth, net losses rose 51% to $381,536 due to increased R&D and marketing expenses. The company is optimistic about launching the Zimed™ PF product and is working with reVision Therapeutics on the REV-0100 development plan. Overall, the results reflect positive growth yet highlight increasing financial losses.

Aequus Pharmaceuticals announced its second highest quarterly revenue in company history for Q2 2021, reporting $651,516 in promotional services and product sales, a 20% year-over-year increase. Investments in growth, especially in the launch of Evolve products, drove a 114% increase in net losses, totaling $479,041. Year-to-date revenues reached $1,143,337, up by 2% compared to 2020. The company also plans to update its Shelf Prospectus before October 16, 2021, to ensure future financing flexibility.

Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) announces the appointment of Dr. Robert K. Koenekoop as a medical and clinical consultant on inherited retinal diseases. His role aims to support Aequus' collaboration with reVision Therapeutics on REV-0100, a potential therapy for Stargardt disease. Dr. Koenekoop's extensive experience in ophthalmology is expected to advance the REV-0100 program, designed to reduce toxic lipofuscin levels in the retina. Stargardt disease affects 1 in 8-10 thousand people globally, and currently, no approved treatments exist targeting this condition.

Aequus Pharmaceuticals and reVision Therapeutics announced a collaboration to develop a therapy for Stargardt disease, a condition that leads to vision loss with no current treatments. Aequus has the option to acquire North American commercial rights to reVision's REV-0100, which targets toxic lipofuscin buildup in the retina. The FDA has granted REV-0100 Orphan Drug and Rare Pediatric Disease designations, facilitating faster development. Initial funding will support a pre-clinical toxicology study, with clinical trials expected to start in late 2021 or early 2022.